Gastric Inhibitory Peptide (22-51) (human) TFA

Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 μM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.

OC(C(F)(F)F)=O.O=C(O)CC[C@H](N[H])C(N[C@@H](CCCCN[H])C(N[C@@H](CCCCN[H])C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CC1=CNC=N1)C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N2CCC[C@H]2C(N[C@@H](CO)C(N[C@H](C(N3CCC[C@H]3C(N[C@@H](C(C)C)C(NCC(N[C@@H](CO)C(N[C@@H](CC4=CNC=N4)C(N[C@H](C(N[C@@H](CCCCN[H])C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N5CCC[C@H]5C(N[C@@H](CCC(N)=O)C(N6CCC[C@H]6C(N[C@@H](CCCNC(N)=N)C(NCC(N7CCC[C@H]7C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)CC(C)C)=O)=O)=O)CC(C)C)=O)C)=O)=O)CC8=CC=CC=C8)=O)=O)=O)=O)=O)=O